Return to program book search
Biologics Promise and Perils
Friday, March 21
9:00 AM - 12:00 PM
Richard G. B. Langley, MD, FAAD
- Kenneth B. Gordon, MD, FAAD
- Alexandra Boer Kimball, MD, MPH, FAAD
- Nehal N. Mehta, MD
- Amy S. Paller, MD, FAAD
- Neil H. Shear, MD, FAAD
- Bruce Elliot Strober, MD, PhD, FAAD
Following this course, the attendee should be able to:
- Recognize key short and long-term safety issues associated with biologic agents used to treat psoriasis.
- Identify emerging safety issues and updates to safety information for biologic agents.
- Assess the risk/benefit related to the efficacy and safety of biologics in the treatment of psoriasis.
The advent of targeted biologic therapies has provided new treatment options in the management of chronic plaque psoriasis. These agents have been extensively studied in randomized controlled trials and shown excellent efficacy with superiority in certain instances to conventional agents. Still, there are a number of concerns regarding the short term and long-term safety of these agents and the appropriate use of these medications in general, and in certain patient populations. This session will feature a concise, but rigorous review of several important topics involving both the promise and potential perils of the use of biologic agents in the psoriasis patient. Several practical clinical topics will also be addressed in the context of the management of psoriatic patients with biologics and conventional agents. This session will overview both promise and perils in the use of biologic agents and will also consider comparisons, where relevant, with conventional systemic agents. In addition, time will be allocated to an interactive panel for questions and answers with the faculty with audience participation, where additional cases may be presented.